Cargando…

1428. Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination

BACKGROUND: Vaccines are an important factor in combating the growing global health issue of antimicrobial resistance. Pneumococcal conjugate vaccines (PCVs) have substantially reduced the burden of otitis media (OM) caused by S. pneumoniae, one of the largest causes of antibiotic prescriptions (Abx...

Descripción completa

Detalles Bibliográficos
Autores principales:	Breton, Marie-Claude, Farkouh, Raymond, Vojicic, Jelena, Wilson, Michele, McDade, Cheryl, Wasserman, Matt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253390/ http://dx.doi.org/10.1093/ofid/ofy210.1259

Ejemplares similares

Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
por: Wilson, Michele, et al.
Publicado: (2018)

Pneumococcal Vaccination Provides Substantial Value for Money for Canadians
por: Peloquin, Francois, et al.
Publicado: (2017)

Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
por: Wasserman, Matt D., et al.
Publicado: (2018)

Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”
por: Wilson, Michele R., et al.
Publicado: (2018)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis
por: Wilson, Michele R., et al.
Publicado: (2020)

Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium
por: Wilson, Michele R., et al.
Publicado: (2021)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
por: Wasserman, Matt, et al.
Publicado: (2019)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
por: Wasserman, Matthew, et al.
Publicado: (2018)

Pneumococcal Conjugate Vaccines and Otitis Media
por: Taylor, Sylvia, et al.
Publicado: (2012)

Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
por: Fletcher, Mark A., et al.
Publicado: (2012)

2728. Proportion of Invasive Pneumococcal Disease Potentially Covered by Current and Next-Generation of Higher-Valency Pneumococcal Conjugate Vaccines in Canada, 2010–2016
por: Dion, Stephane B, et al.
Publicado: (2019)

Impact of Pneumococcal Conjugate Vaccination on Otitis Media: A Systematic Review
por: Taylor, Sylvia, et al.
Publicado: (2012)

Erratum to “Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials”
por: Fletcher, Mark A., et al.
Publicado: (2012)

Pneumococcal Otitis Media by Contagion
Publicado: (1909)

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
por: Perdrizet, Johnna, et al.
Publicado: (2023)

Otitis Media in Fully Vaccinated Preschool Children in the Pneumococcal Conjugate Vaccine Era
por: Talathi, Saurabh, et al.
Publicado: (2017)

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age
por: Wasserman, Matt D., et al.
Publicado: (2021)

Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
por: Pugh, Sarah J., et al.
Publicado: (2018)

2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children
por: Hulten, Kristina G, et al.
Publicado: (2019)

1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
por: Vojicic, Jelena, et al.
Publicado: (2018)

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
por: Wilson, Michele, et al.
Publicado: (2023)

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’
por: Rozenbaum, Mark H., et al.
Publicado: (2022)

Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media
por: Izurieta, Patricia, et al.
Publicado: (2022)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
por: Wasserman, Matt, et al.
Publicado: (2021)

1384. Conceptual Economic Model Methodology for Infant Pneumococcal Conjugate Vaccine Program and its Impact on Antimicrobial Resistance
por: Farkouh, Raymond, et al.
Publicado: (2020)

Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
por: Leach, Amanda Jane, et al.
Publicado: (2014)

Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine
por: Levy, Corinne, et al.
Publicado: (2019)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France
por: Cohen, Robert, et al.
Publicado: (2012)

Influence of Pneumococcal Conjugate Vaccine on Acute Otitis Media with Severe Middle Ear Inflammation: A Retrospective Multicenter Study
por: Sugino, Hirotoshi, et al.
Publicado: (2015)

Acute otitis media and pneumococcal vaccination – an observational cross-sectional study of otitis media among vaccinated and unvaccinated children in Greenland
por: Jespersen, Simon Imer, et al.
Publicado: (2021)

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
por: Shen, Kunling, et al.
Publicado: (2018)

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis
por: Pugh, Sarah, et al.
Publicado: (2020)

Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK
por: Wasserman, M., et al.
Publicado: (2018)

Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia
por: Carrasquilla, Gabriel, et al.
Publicado: (2020)

The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Otitis Media–Related Antibiotic Use Among Young Children in Tennessee, USA
por: Griffith, Hannah, et al.
Publicado: (2022)

Biofilm-Forming Bacteria Implicated in Complex Otitis Media in Children in the Post-Heptavalent Pneumococcal Conjugate Vaccine (PCV7) Era
por: Ioannidis, Anastasios, et al.
Publicado: (2023)

Ultrastructural characteristics of the round window membrane during pneumococcal otitis media in rat.
por: Yoon, Yong-Joo, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_u2vhdik2ldsu0ourf23dieufli